PDCD1 and melanoma: In the latest clinical trial of mRNA-4157, encoding up to 34 different neoantigens, in high-risk melanoma, the combination with mRNA-4157 and anti-PD-1 significantly prolonged distant-metastasis-free survival and reduced the risk of developing distant metastases or death by 65% compared to pembrolizumab alone [410].